Royalty Pharma (RPRX) Other financing activities (2020 - 2026)

Royalty Pharma (RPRX) has 4 years of Other financing activities data on file, last reported at -$226000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to -$226000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.0 million (down 201700.0% YoY), and the FY2025 full-year result was -$1.8 million, up 80.17% from the prior year.
• Other financing activities grew to -$226000.0 in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $2000.0 in Q3 2024 to a low of -$1.8 million in Q4 2025.
• A 3-year average of -$503750.0 and a median of -$113500.0 in 2024 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 178900.0% in 2025, while the deepest fall reached 178900.0% in 2025.
• Tracing RPRX's Other financing activities over 3 years: stood at -$1000.0 in 2024, then tumbled by 178900.0% to -$1.8 million in 2025, then surged by 87.37% to -$226000.0 in 2026.
• Business Quant data shows RPRX's Other financing activities at -$226000.0 in Q1 2026, -$1.8 million in Q4 2025, and -$1000.0 in Q4 2024.